Search Results
Your search for ,WHo matches 20680 pages
Showing 19301 - 19350Experimental Immunotherapy Delays Recurrence for Stage III and IV Ovarian Cancers
According to a phase II study presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, an experimental immunotherapy is in the works that can target an individual woman’s ovarian tumor and extend the time period between initial treatment and the cancer’s...
ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline, Announce Opening of Public Comment Period
The American Society for Clinical Pathology (ASCP), the College of American Pathologists (CAP), the Association for Molecular Pathology (AMP), and the American Society of Clinical Oncology (ASCO) today released a draft of a clinical practice guideline on the use of molecular marker testing for...
Panobinostat and Carfilzomib Combination Appears Safe and Effective in Relapsed/Refractory Multiple Myeloma
In patients with relapsed/refractory multiple myeloma, the combination of panobinostat (Farydak) and carfilzomib (Kyprolis) appears to be safe and effective, according to a phase I/II study by Berdeja et al in Haematologica. Further evaluation of this combination treatment is warranted to establish ...
FDA Grants Priority Review to Carfilzomib Supplemental New Drug Application for Relapsed Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has accepted Amgen’s supplemental New Drug Application (sNDA) for carfilzomib (Kyprolis) injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. The sNDA is designed to support the...
No Survival Benefit of IGF-1R/Insulin Receptor Inhibitor Linsitinib in Advanced Adrenocortical Carcinoma
In a phase III trial reported in The Lancet Oncology, Fassnacht et al found that linsitinib, an insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor inhibitor, did not improve overall survival vs placebo in patients with previously treated locally advanced or metastatic...
Women With Diabetes More Likely to be Diagnosed With Advanced-Stage Breast Cancer
Diabetes is associated with more advanced stage breast cancer, according to a new study by the Institute for Clinical Evaluative Sciences (ICES) and Women's College Hospital. The findings, published by Lipscombe et al in Breast Cancer Research and Treatment, confirm a strong link between diabetes...
Younger Men Who Survive 10 Years After Radical Prostatectomy Are More Likely to Die of Non–Cancer-Related Causes
A new study suggests that after radical prostatectomy for high-risk prostate cancer, both the age of the patient and the time survived since the operation have a significant impact on the cause of death. This means that, for young men with high-risk prostate cancer, doctors may have to reevaluate...
Smokers Have Twice the Risk of Prostate Cancer Recurrence After Surgery as Never-Smokers
Current smokers, and those who have quit smoking less than 10 years previously, have twice the risk of a recurrence of prostate cancer after surgery, according to new research by Rieken et al presented at the European Association of Urology (EAU) 2015 Congress in Madrid (Abstract 508). In 2012,...
Marked Increase in Fracture Risk in Patients Receiving Hematopoietic Stem Cell Transplantation
In a single-institution retrospective study reported in the Journal of Clinical Oncology, Pundole et al found that patients undergoing hematopoietic stem cell transplantation are at increased risk of bone fracture later in life, with risk being particularly elevated in women and men aged 45 to 64...
Study Compares Incidence and Severity of Treatment-Related Neuropathy in Patients With Colorectal Cancer vs Other Cancers
Patients with colorectal cancer experience significantly higher rates of numbness/tingling but comparable neuropathic pain relative to patients with other cancers, according to a study by Lewis et al in the Journal of Pain and Symptom Management. In addition, numbness/tingling was more likely to be ...
Effect of Smoking and Alcohol Consumption on Feeding Tube Duration in Head and Neck Cancer Patients
Current smoking and heavy alcohol consumption appear to be risk factors for prolonged use of a gastrostomy tube in patients with head and neck cancer undergoing radiotherapy or chemoradiotherapy. The findings were published in a report by O’Shea et al in JAMA Otolaryngology-Head & Neck...
New Surgical Algorithm Results in Improved Complete Resection Rates in Advanced Ovarian Cancer
A surgical algorithm developed and implemented by ovarian cancer specialists at The University of Texas MD Anderson Cancer Center dramatically increases the frequency of complete removal of all visible tumor—a milestone strongly tied to improved chances of survival. The researchers describe...
Decline in Proportion of Lung Cancer Patients Meeting Screening Criteria
In a study reported in a research letter in JAMA, Wang et al found that the proportion of patients with lung cancer who would have met U.S. Preventive Services Task Force (USPSTF) criteria for low-dose computed tomography (CT) lung screening decreased significantly between the periods of 1984 to...
PET-Adapted Sequential Salvage Therapy With Brentuximab and Augmented ICE Produces High Response Rate in Relapsed/Refractory Hodgkin Lymphoma
In a phase II study reported in The Lancet Oncology, Moskowitz et al found that a salvage strategy involving brentuximab vedotin (Adcetris) treatment followed by 18F-fluorodeoxyglucose positron-emission tomography (PET) and augmented ifosfamide, carboplatin, and etoposide (ICE) in PET-positive...
No Difference in Event-Free Survival With Stem Cell Transplantation Using Matched Unrelated vs Sibling Donor Grafts in Children With ALL
In a European trial (Berlin-Frankfurt-Muenster study group trial ALL-SCT-BFM 2003) reported in the Journal of Clinical Oncology, Peters et al found no difference in event-free survival with stem cell transplantation using matched unrelated vs sibling donors in pediatric patients with high-risk...
Measuring Minimal Residual Disease Levels Proves to Be a Powerful Tool for Guiding Leukemia Treatment
According to a prospective study led by researchers at St. Jude Children's Research Hospital, measuring the concentration of leukemia cells in patient bone marrow during the first 46 days of chemotherapy may help boost survival of young leukemia patients by better matching patients with the right...
European Retrospective Study Shows Activity of Crizotinib in Advanced Lung Adenocarcinoma With ROS1 Rearrangement
In a retrospective study in the European EUROS1 cohort reported in the Journal of Clinical Oncology, Mazières found that crizotinib (Xalkori) treatment was associated with an 80% response rate in patients with stage IV lung adenocarcinoma with ROS1 rearrangement. Study Details The study...
Nivolumab Shows Activity in Advanced, Refractory Squamous NSCLC
In the phase II CheckMate 063 study reported in The Lancet Oncology, Rizvi et al found that the PD-1 inhibitor nivolumab (Opdivo) produced durable responses in some patients with advanced, refractory squamous non–small cell lung cancer (NSCLC) who had received at least two prior treatments....
Addition of Aprepitant to Ondansetron Effective in Preventing Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients
In a phase III trial reported in The Lancet Oncology, Kang et al found that adding aprepitant to ondansetron with or without dexamethasone was effective in preventing chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately or highly emetogenic chemotherapy. Study...
New Breast Cancer Test Links Immune ‘Hotspots’ to Better Survival
Scientists have developed a new test that predicts the survival chances of women with breast cancer by analyzing images of “hotspots” where there has been a fierce immune reaction to a tumor. Using statistical software previously used in criminology studies of crime hotspots,...
NIH-Funded Study Suggests Novel Strategy to Improve Vaccine Efficacy in the Treatment of Glioblastoma
Although dendritic cell–based immunotherapy has shown limited promise in the treatment of patients with advanced cancers, including glioblastoma, the factors dictating dendritic cell–based vaccine efficacy have been poorly understood. Now, a clinical trial funded by the National...
Breast Cancer Risk May Increase in Women Who Have First-Degree Relatives With a History of Prostate Cancer
Having a family history of prostate cancer among first-degree relatives may increase a woman's risk of developing breast cancer. Researchers from multiple institutions published their findings in a study by Beebe-Dimmer et al in Cancer. The study's results indicate that clinicians should take a...
Outcomes of Phase II Basket Trial of Molecular Profiling and Targeted Therapy in Advanced Thoracic Malignancies
In a basket trial (CUSTOM) reported in the Journal of Clinical Oncology, Lopez-Chavez et al performed molecular profiling of tumors in patients with advanced non–small cell lung cancer (NSCLC), small cell lung cancer, or thymic malignancies and assigned those in any of five actionable...
Maintenance Sunitinib Improves Progression-Free Survival in Phase II Trial in Untreated Extensive-Stage Small Cell Lung Cancer
In the randomized phase II Cancer and Leukemia Group B (CALGB) 30504/Alliance trial reported in the Journal of Clinical Oncology, Ready et al found that sunitinib (Sutent) vs placebo maintenance following chemotherapy improved progression-free survival in patients with previously untreated...
Annual ASCO Report Shows Widespread Disturbance in Oncology Practice, Amid Growing Patient Demand and Administrative Burden
The U.S. cancer care system faces tremendous turbulence while dealing with growing numbers of cancer patients and survivors, mounting pressures to control rising health-care costs, and widespread oncology practice transformation, reports a new study by the American Society of Clinical Oncology...
NCCN Publishes New Guidelines for Smoking Cessation
Tobacco-related diseases are the most preventable cause of death worldwide; smoking cessation leads to improvement in cancer treatment outcomes, as well as decreased tumor recurrence. According to the American Cancer Society, in 2015, nearly 171,000 of the estimated 589,430 cancer deaths in the...
Concurrent Chemoradiation Therapy at High-Volume Facilities Improves Survival for NSCLC
Patients treated with definitive concurrent chemotherapy and radiation therapy for stage III non–small cell lung cancer (NSCLC) have longer overall survival when treated by highly experienced facilities, whether or not they are academic or community cancer centers. Researchers from the Yale...
Study Finds Lycopene May Be Associated With Lower Risk for Kidney Cancer in Postmenopausal Women
A higher intake by postmenopausal women of lycopene, an antioxidant found in foods like tomatoes, watermelon, and papaya, may lower the risk of renal cell carcinoma, a type of kidney cancer. A study describing these findings was published by Ho et al in Cancer. In 2014, 63,920 estimated new cases...
Clinical Trial Suggests Temozolomide-Based Chemoradiation Is Best for Low-Grade Brain Tumors
New clinical trial findings provide further evidence that combining chemotherapy with radiation therapy is the best treatment for people with a low-grade form of brain cancer. The findings come from a phase II study co-led by a researcher at Ohio State University Comprehensive Cancer...
Similar Local Recurrence Rates But Increased Distant Metastases With Adjuvant Localized vs Whole-Brain Radiotherapy in Patients With Brain Metastases
In patients who had undergone surgery for brain metastases, the rate of recurrence at the resected site was similar between patients who received adjuvant whole-brain radiotherapy vs those who underwent adjuvant localized radiotherapy, according to a retrospective study by Hsieh et al in the...
Durable Responses at 3-Year Follow-up for CLL Patients Receiving Single-Agent Ibrutinib
At a median follow-up of 3 years, ibrutinib (Imbruvica) demonstrated continued activity with durable responses that improved in quality with extended treatment of patients with chronic lymphocytic leukemia (CLL). In addition, grade 3 toxicity and adverse events leading to discontinuation diminished ...
EGFR L858R Mutation in Circulating Free DNA From Blood Samples of Patients With Non–Small Cell Lung Cancer Shown to Be Negative Prognostic Marker
Using a novel polymerase chain reaction assay “to efficiently assess” epidermal growth factor receptor (EGFR) mutations in circulating free DNA (cfDNA) from blood samples of patients with advanced non–small cell lung cancer (NSCLC), the Spanish Lung Cancer Group has “shown...
Age-Stratified Predictive Model May Provide Surgical Guidelines for Uterine Leiomyomas
A study by Brohl et al investigating the case incidence of unexpected uterine sarcoma following surgery for presumed benign leiomyoma (fibroids or myomas) has found that the risk of unexpected uterine sarcoma varies significantly across age groups, with a more than fivefold difference between the...
New Analysis Reports Increased Risk of Thyroid Cancer After Breast Cancer Diagnosis
Breast cancer survivors are at increased risk of developing thyroid cancer, especially within 5 years of their breast cancer diagnosis, according to a new analysis of a large national database. The study results were presented at the Endocrine Society's 97th Annual Meeting. “Recognition of...
AACR Names Nancy E. Davidson, MD, President-Elect for 2015-2016
The American Association for Cancer Research (AACR) today announced the election of Nancy E. Davidson, MD, Director of the University of Pittsburgh Cancer Institute and UPMC CancerCenter in Pittsburgh, as its President-Elect for 2015–2016. Dr. Davidson will officially become President-Elect...
FDA Approves Dinutuximab Combination for Pediatric Patients With High-Risk Neuroblastoma
The U.S. Food and Drug Administration has approved dinutuximab (Unituxin) as part of first-line therapy for pediatric patients with high-risk neuroblastoma. Dinutuximab, a chimeric monoclonal antibody that binds to the surface of neuroblastoma cells, is being approved for use as part of a...
Neoadjuvant Chemotherapy for Breast Cancer Increases Chances of Lumpectomy, Decreases Chances of Mastectomy
Patients with larger malignant tumors of the breast who undergo chemotherapy before a breast cancer operation are more likely to undergo a lumpectomy than a mastectomy, according to a study published by Killelea et al in the Journal of the American College of Surgeons. Study investigators from...
Inherited Gene Variation Leaves Young Leukemia Patients at Risk for Peripheral Neuropathy
St. Jude Children’s Research Hospital scientists have identified the first genetic variation that is associated with an increased risk and severity of peripheral neuropathy following treatment with a widely used anticancer drug. Investigators also found evidence of how it may be possible to...
Complex Surgery Does Not Independently Predict Outcome in Advanced Ovarian Cancer
In an analysis in the Gynecologic Oncology Group (GOG 182) trial population reported in the Journal of Clinical Oncology, Horowitz et al found that more complex surgery was not an independent predictor of progression-free or overall survival among patients with advanced epithelial ovarian or...
Immunologic Factors Predict Pathologic Complete Response to Neoadjuvant Therapy With or Without Carboplatin in Breast Cancer
In a study reported in the Journal of Clinical Oncology, Denkert et al found that increased tumor-infiltrating lymphocytes and the presence of lymphocyte-predominant breast cancer were associated with increased rates of pathologic complete response in patients receiving neoadjuvant...
Acceptable Cardiac Safety of Ado-Trastuzumab Emtansine After Anthracycline-Based Chemotherapy in Early-Stage HER2-Positive Breast Cancer
In a study reported in the Journal of Clinical Oncology, Krop et al found that ado-trastuzumab emtansine (Kadcyla) had an acceptable cardiac safety profile when used after anthracycline-based (neo)adjuvant therapy in women with early-stage HER2-positive breast cancer. Study Details In the study,...
New Study Assesses Inclusion of Family in Cancer Patients’ Treatment Decisions
Family members often play an important role in providing care for patients with cancer, but which patients are more or less likely to involve family members in decisions regarding their care is not well known. A new study published by Hobbs et al in Cancer provides some insights and may help...
Lower Household Net Worth and Black Race Associated With Nonadherence to Hormonal Therapy for Early-Stage Breast Cancer
In a study reported in the Journal of Clinical Oncology, Hershman et al found that nonadherence to adjuvant hormonal therapy for early-stage breast cancer was more common among black women and patients with lower household net worth, with the latter factor partly accounting for the racial...
Colorectal Cancer Benefits With Flexible Sigmoidoscopy Screening in SCORE Trial Are Generalizable to Broader Population
The Italian SCORE trial is among several recent large European randomized trials showing the benefit of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality. In a study reported in the Journal of the National Cancer Institute, Senore et al found that characteristics of...
FDA Approves First Biosimilar Product Filgrastim‑Sndz
The U.S. Food and Drug Administration (FDA) today approved filgrastim-sndz (Zarxio), the first biosimilar product approved in the United States. A biosimilar product is a biologic product that is approved based on a showing that it is highly similar to an already-approved biologic. The biosimilar...
Preclinical Study Shows Promise for the Development of Personalized Cellular Therapy for Brain Cancer
Immune cells engineered to seek out and attack a type of deadly brain cancer were found to be safe and effective at controlling tumor growth in mice that were treated with these modified cells, according a team from the Perelman School of Medicine at the University of Pennsylvania and the Novartis...
No Improvement in Overall Survival With Addition of Anti-EGFR Antibody Necitumumab to First-Line Pemetrexed-Cisplatin in Metastatic Nonsquamous NSCLC
In the phase III INSPIRE trial reported in The Lancet Oncology, Paz-Ares et al found that the addition of the anti-EGFR IgG1 monoclonal antibody necitumumab to first-line pemetrexed (Alimta)-cisplatin did not improve overall survival in patients with previously untreated stage IV nonsquamous...
Harold Varmus, MD, Stepping Down as Director of the National Cancer Institute
Harold Varmus, MD, who has led the National Cancer Institute (NCI) at the National Institutes of Health (NIH) for nearly 5 years, has announced that he will step down from his post, effective March 31, 2015. Dr. Varmus will be joining Weill Cornell Medical College's faculty as the Lewis Thomas...
Aurora Kinase A Inhibitor Alisertib Active in Solid Tumors
In a phase II study reported in The Lancet Oncology, Melichar et al found that the oral aurora kinase A inhibitor alisertib was active in solid tumors, particularly breast cancer and small cell lung cancer. Aurora kinases play central roles in mitosis. Inhibition of aurora kinase A, which is...
Study Finds Websites That Market Personalized Cancer Care Services Overemphasize Benefits
A recent analysis of 55 Internet websites marketing a broad range of tests and services that promise the ability to personalize cancer treatment has found that the websites often overemphasize their purported benefits and downplay their limitations. In addition, the study results show that the...
